Atria Investments Inc Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Atria Investments Inc boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 72.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,165 shares of the life sciences company’s stock after acquiring an additional 8,902 shares during the period. Atria Investments Inc’s holdings in Illumina were worth $2,906,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ILMN. Raymond James Financial Services Advisors Inc. lifted its position in Illumina by 22.6% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 8,576 shares of the life sciences company’s stock valued at $1,194,000 after acquiring an additional 1,582 shares during the last quarter. Fifth Third Bancorp lifted its position in Illumina by 10.6% during the fourth quarter. Fifth Third Bancorp now owns 4,412 shares of the life sciences company’s stock valued at $614,000 after acquiring an additional 424 shares during the last quarter. Ballentine Partners LLC purchased a new stake in Illumina during the fourth quarter valued at approximately $478,000. Clear Creek Financial Management LLC increased its stake in Illumina by 6.3% during the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares in the last quarter. Finally, Private Trust Co. NA increased its stake in Illumina by 42.9% during the 4th quarter. Private Trust Co. NA now owns 756 shares of the life sciences company’s stock valued at $105,000 after purchasing an additional 227 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price target on the stock in a research note on Wednesday, July 10th. TD Cowen cut their price target on shares of Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research note on Thursday, June 6th. Jefferies Financial Group initiated coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Evercore ISI cut their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 11th. Finally, StockNews.com started coverage on shares of Illumina in a research note on Sunday, June 30th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $158.57.

Illumina Stock Performance

ILMN stock traded down $4.65 during midday trading on Friday, hitting $117.70. 1,824,098 shares of the stock traded hands, compared to its average volume of 1,642,188. The firm has a market cap of $18.75 billion, a P/E ratio of -14.44 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock’s fifty day simple moving average is $111.29 and its 200-day simple moving average is $123.67. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $195.64.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm’s revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the business earned $0.08 earnings per share. On average, analysts expect that Illumina, Inc. will post 1.5 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.